Rejection of Leukemic Cells Requires Antigen-Specific TCells with High Functional Avidity

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 1, 2014, Pages 37-45

  Vincent, Krystel ^a,b   Hardy, Marie Pierre ^a,b   Trofimov, Assya ^a,b   Laumont, Céline M ^a,b   Sriranganadane, Dev ^a,b   Hadj Mimoune, Sarah ^a,b   Salem Fourati, Insaf ^b   Soudeyns, Hugo ^b   Thibault, Pierre ^a,b   Perreault, Claude ^a,b  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

CD8 T lymphocyte; Leukemia immunotherapy; Leukemia associated antigen; Major histocompatibility complex; Minor histocompatibility antigen

Indexed keywords

EPITOPE; LEUKEMIA ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENSITY; FEMALE; GENE OVEREXPRESSION; IMMUNIZATION; LEUKEMIA CELL; MALE; MOUSE; NONHUMAN; SURFACE PROPERTY; THYMOCYTE;

CD8 T LYMPHOCYTE; LEUKEMIA IMMUNOTHERAPY; LEUKEMIA-ASSOCIATED ANTIGEN; MAJOR HISTOCOMPATIBILITY COMPLEX; MINOR HISTOCOMPATIBILITY ANTIGEN;

ANIMALS; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; FEMALE; GENE EXPRESSION; IMMUNIZATION; IMMUNOTHERAPY, ADOPTIVE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MICE; MICE, TRANSGENIC; MINOR HISTOCOMPATIBILITY ANTIGENS; PEPTIDES; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; THYMOCYTES;

EID: 84890955814     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.10.020     Document Type: Article

References (75)

1. Bleakley M., Riddell S.R. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer 2004, 4:371-380.
2. Vincent K., Roy D.C., Perreault C. Next-generation leukemia immunotherapy. Blood 2011, 118:2951-2959.
3. Jenq R.R., van den Brink M.R. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer 2010, 10:213-221.
4. Hsieh M.H., Patterson A.E., Korngold R. T-cell subsets mediate graft-versus-myeloid leukemia responses via different cytotoxic mechanisms. Biol Blood Marrow Transplant 2000, 6:231-240.
5. Hsieh M.H., Korngold R. Differential use of FasL- and perforin-mediated cytolytic mechanisms by T-cell subsets involved in graft-versus-myeloid leukemia responses. Blood 2000, 96:1047-1055.
6. Reddy P., Maeda Y., Liu C., et al. Acrucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med 2005, 11:1244-1249.
7. Schmaltz C., Alpdogan O., Kappel B.J., et al. Tcells require TRAIL for optimal graft-versus-tumor activity. Nat Med 2002, 8:1433-1437.
8. + T cells require direct leukemic contact to mediate GVL. Blood 2008, 111:3884-3892.
9. Spierings E., Drabbels J., Hendriks M., et al. Auniform genomic minor histocompatibility antigen typing methodology and database designed to facilitate clinical applications. PLoS ONE 2006, 1:e42.
10. Roopenian D., Choi E.Y., Brown A. The immunogenomics of minor histocompatibility antigens. Immunol Rev 2002, 190:86-94.
11. Spierings E., Hendriks M., Absi L., et al. Phenotype frequencies of autosomal minor histocompatibility antigens display significant differences among populations. PLoS Genet 2007, 3:e103.
12. Warren E.H., Zhang X.C., Li S., et al. Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT. Blood 2012, 120:2796-2806.
13. Pion S., Fontaine P., Baron C., et al. Immunodominant minor histocompatibility antigens expressed by mouse leukemic cells can serve as effective targets for T cell immunotherapy. JClin Invest 1995, 95:1561-1568.
14. Hobo W., Broen K., van der Velden W.J., et al. Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host-disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2013, 19:274-282.
15. Broen K., Greupink-Draaisma A., Fredrix H., et al. Induction of multiple myeloma-reactive T cells during post-transplantation immunotherapy with donor lymphocytes and recipient DCs. Bone Marrow Transplant 2012, 47:1229-1234.
16. Hambach L., Goulmy E. Immunotherapy of cancer through targeting of minor histocompatibility antigens. Curr Opin Immunol 2005, 17:202-210.
17. Spierings E., Kim Y.H., Hendriks M., et al. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013, 19:1244-1253.
18. Hambach L., Nijmeijer B.A., Aghai Z., et al. Human cytotoxic T lymphocytes specific for a single minor histocompatibility antigen HA-1 are effective against human lymphoblastic leukaemia in NOD/scid mice. Leukemia 2006, 20:371-374.
19. Hambach L., Vermeij M., Buser A., Aghai Z., van der Kwast T., Goulmy E. Targeting a single mismatched minor histocompatibility antigen with tumor-restricted expression eradicates human solid tumors. Blood 2008, 112:1844-1852.
20. Molldrem J.J., Lee P.P., Wang C., et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000, 6:1018-1023.
21. Rezvani K., Yong A.S., Savani B.N., et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 2007, 110:1924-1932.
22. Lindahl K.F. Minor histocompatibility antigens. Trends Genet 1991, 7:219-224.
23. Dupage M., Mazumdar C., Schmidt L.M., et al. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012, 482:405-409.
24. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. NEngl J Med 2013, 368:2059-2074. The Cancer Genome Atlas Research Network.
25. van den Brink M.R., Porter D.L., Giralt S., et al. Relapse after allogeneic hematopoietic cell therapy. Biol Blood Marrow Transplant 2010, 16:S138-S145.
26. Miller J.S., Warren E.H., van den Brink M.R., et al. NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: graft-versus-tumor/leukemia reaction. Biol Blood Marrow Transplant 2010, 16:565-586.
27. de Verteuil D., Muratore-Schroeder T.L., Granados D.P., et al. Deletion of immunoproteasome subunits imprints on the transcriptome and has a broad impact on peptides presented by major histocompatibility complex I molecules. Mol Cell Proteomics 2010, 9:2034-2047.
28. Caron E., Vincent K., Fortier M.H., et al. The MHC I immunopeptidome conveys to the cell surface an integrative view of cellular regulation. Mol Syst Biol 2011, 7:533.
29. Rock K.L., Gramm C., Benacerraf B. Low temperature and peptides favor the formation of class I heterodimers on RMA-S cells at the cell surface. Proc Natl Acad Sci U S A 1991, 88:4200-4204.
30. Kessler J.H., Mommaas B., Mutis T., et al. Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides. Hum Immunol 2003, 64:245-255.
31. Roy-Proulx G., Baron C., Perreault C. CD8 T-cell ability to exert immunodomination correlates with T-cell receptor:epitope association rate. Biol Blood Marrow Transplant 2005, 11:260-271.
32. Fortier M.H., Caron E., Hardy M.P., et al. The MHC class I peptide repertoire is molded by the transcriptome. JExp Med 2008, 205:595-610.
33. Tan C.T., Croft N.P., Dudek N.L., et al. Direct quantitation of MHC-bound peptide epitopes by selected reaction monitoring. Proteomics 2011, 11:2336-2340.
34. Zuberi A.R., Christianson G.J., Mendoza L.M., et al. Positional cloning and molecular characterization of an immunodominant cytotoxic determinant of the mouse H3 minor histocompatibility complex. Immunity 1998, 9:687-698.
35. b minor histocompatibility antigen is caused by a combination of genetically determined and posttranslational modifications. JImmunol 2003, 170:5133-5142.
36. dom1) encoded by the classical H7 minor histocompatibility locus. JImmunol 1999, 162:4502-4510.
37. dom1 minor histocompatibility antigen is encoded by a mouse homolog of the yeast STT3 gene. Immunogenetics 2002, 54:562-569.
38. Mendoza L.M., Paz P., Zuberi A., et al. Minors held by majors: the H13 minor histocompatibility locus defined as a peptide-MHC class I complex. Immunity 1997, 7:461-472.
39. Ostrov D.A., Roden M.M., Shi W., et al. How H13 histocompatibility peptides differing by a single methyl group and lacking conventional MHC binding anchor motifs determine self-nonself discrimination. JImmunol 2002, 168:283-289.
40. Roderick T.H., Guidi J.N. Strain distribution of polymorphic variants. Genetic variants and strains of the laboratory mouse 1989, 663-772. Oxford University Press, Oxford. M.F. Lyon, A.G. Searle (Eds.).
41. Fontaine P., Roy-Proulx G., Knafo L., et al. Adoptive transfer of Tlymphocytes targeted to a single immunodominant minor histocompatibility antigen eradicates leukemia cells without causing graft-versus-host disease. Nat Med 2001, 7:789-794.
42. Laugel B., van den Berg H.A., Gostick E., et al. Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding properties. JBiol Chem 2007, 282:23799-23810.
43. Stone J.D., Artyomov M.N., Chervin A.S., et al. Interaction of streptavidin-based peptide-MHC oligomers (tetramers) with cell-surface TCRs. JImmunol 2011, 187:6281-6290.
44. Davis M.M., Altman J.D., Newell E.W. Interrogating the repertoire: broadening the scope of peptide-MHC multimer analysis. Nat Rev Immunol 2011, 11:551-558.
45. Bihl F., Frahm N., Di Giammarino L., et al. Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. JImmunol 2006, 176:4094-4101.
46. Gallimore A., Dumrese T., Hengartner H., et al. Protective immunity does not correlate with the hierarchy of virus- specific cytotoxic T cell responses to naturally processed peptides. JExp Med 1998, 187:1647-1657.
47. Busch D.H., Pamer E.G. MHC class I/peptide stability: implications for immunodominance, invitro proliferation, and diversity of responding CTL. JImmunol 1998, 160:4441-4448.
48. Pion S., Christianson G.J., Fontaine P., et al. Shaping the repertoire of cytotoxic T-lymphocyte responses: explanation for the immunodominance effect whereby cytotoxic T lymphocytes specific for immunodominant antigens prevent recognition of nondominant antigens. Blood 1999, 93:952-962.
49. Wherry E.J., Puorro K.A., Porgador A., Eisenlohr L.C. The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. JImmunol 1999, 163:3735-3745.
50. Yewdell J.W., Bennink J.R. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 1999, 17:51-88.
51. Bullock T.N., Colella T.A., Engelhard V.H. The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice. JImmunol 2000, 164:2354-2361.
52. Derby M.A., Alexander-Miller M.A., Tse R., Berzofsky J.A. High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. JImmunol 2001, 166:1690-1697.
53. Roy-Proulx G., Meunier M.C., Lanteigne A.M., et al. Immunodomination results from functional differences between competing CTL. Eur J Immunol 2001, 31:2284-2292.
54. + T-cell polyfunctionality and HIV-suppressive activity. Blood 2009, 113:6351-6360.
55. + T-cell epitopes in the murine intranasal challenge model. Eur J Immunol 2009, 39:717-722.
56. Berger C.T., Frahm N., Price D.A., et al. High-functional-avidity cytotoxic Tlymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control. JVirol 2011, 85:9334-9345.
57. Jenkins M.K., Moon J.J. The role of naïve T cell precursor frequency and recruitment in dictating immune response magnitude. JImmunol 2012, 188:4135-4140.
58. off rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer. Sci Transl Med 2013, 5:192ra87.
59. Zhong S., Malecek K., Johnson L.A., et al. T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proc Natl Acad Sci U S A 2013, 110:6973-6978.
60. Granados D.P., Yahyaoui W., Laumont C.M., et al. MHC I-associated peptides preferentially derive from transcripts bearing miRNA recognition elements. Blood 2012, 119:e181-e191.
61. Karosiene E., Lundegaard C., Lund O., Nielsen M. NetMHCcons: a consensus method for the major histocompatibility complex class I predictions. Immunogenetics 2012, 64:177-186.
62. + T cell immunodominance. JImmunol 2008, 181:2124-2133.
63. + T cells is reflected by their avidity, polyfunctionality, and clonal turnover. JExp Med 2007, 204:2473-2485.
64. Perreault C., Roy D.C., Fortin C. Immunodominant minor histocompatibility antigens: the major ones. Immunol Today 1998, 19:69-74.
65. Burrows S.R., Kienzle N., Winterhalter A., Bharadwaj M., Altman J.D., Brooks A. Peptide-MHC class I tetrameric complexes display exquisite ligand specificity. JImmunol 2000, 165:6229-6234.
66. Buslepp J., Zhao R., Donnini D., et al. Tcell activity correlates with oligomeric peptide-major histocompatibility complex binding on T cell surface. JBiol Chem 2001, 276:47320-47328.
67. Hernandez J., Lee P.P., Davis M.M., Sherman L.A. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire. JImmunol 2000, 164:596-602.
68. de Verteuil D., Granados D.P., Thibault P., Perreault C. Origin and plasticity of MHC I-associated self peptides. Autoimmun Rev 2012, 11:627-635.
69. Purbhoo M.A., Irvine D.J., Huppa J.B., Davis M.M. Tcell killing does not require the formation of a stable mature immunological synapse. Nat Immunol 2004, 5:524-530.
70. Wiedemann A., Depoil D., Faroudi M., Valitutti S. Cytotoxic T lymphocytes kill multiple targets simultaneously via spatiotemporal uncoupling of lytic and stimulatory synapses. Proc Natl Acad Sci U S A 2006, 103:10985-10990.
71. Morgan R.A., Chinnasamy N., Abate-Daga D., et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. JImmunother 2013, 36:133-151.
72. St-Pierre C., Brochu S., Vanegas J.R., et al. Transcriptome sequencing of neonatal thymic epithelial cells. Sci Rep 2013, 3:1860.
73. Ochsenreither S., Majeti R., Schmitt T., et al. Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. Blood 2012, 119:5492-5501.
74. Robbins P.F., Lu Y.C., El-Gamil M., et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013, 19:747-752.
75. Aleksic M., Dushek O., Zhang H., et al. Dependence of T cell antigen recognition on T cell receptor-peptide MHC confinement time. Immunity 2010, 32:163-174.